Enanta Pharmaceuticals Cuts Q2 Net Loss, Secures Cash Runway to 2029, Advances Pipeline, and Holds Pfizer Patent Arguments

summarizeSummary

Enanta Pharmaceuticals reported a significantly reduced net loss for its fiscal second quarter, extending its cash runway into fiscal 2029, while also providing positive updates on its clinical pipeline and ongoing patent litigation against Pfizer.

check_boxKey Events

• Reduced Net Loss

  Reported a net loss of $13.1 million ($0.45/share) for Q2 2026, a significant improvement from $22.6 million ($1.06/share) in Q2 2025.

• Extended Cash Runway

  Confirmed cash and marketable securities of $227.0 million at March 31, 2026, expected to fund operations into fiscal 2029.

• Pipeline Advancement

  Initiated Phase 1 dosing for EDP-978 (chronic urticaria), is on track for IND filing for EPS-3903 (atopic dermatitis), and plans to select an MRGPRX2 candidate in 2H 2026.

• Pfizer Patent Litigation Update

  Oral arguments were held today (May 11, 2026) at the Federal Circuit in its lawsuit against Pfizer, with a decision anticipated by the end of September 2026. A Unified Patent Court hearing is scheduled for September 29, 2026.

auto_awesomeAnalysis

Enanta Pharmaceuticals demonstrated strong financial health by significantly reducing its net loss and securing a cash runway into fiscal 2029, which de-risks its operations for several years. This financial stability supports the continued advancement of its immunology and RSV pipelines, including the initiation of a Phase 1 trial for EDP-978 and progress towards IND filings. The update on the high-stakes patent litigation against Pfizer, with oral arguments now completed, is a critical development that could have a material impact on the company's future.